Endo Pharmaceuticals was created in 1997 by a management buyout at DuPont Merck. At that time, the CEO, Executive Vice President of Operations, and another colleague purchased Endo Laboratories’ 12 brand products including Percoset, Percodan, and Opana, as well as the company’s generic products.
The company began to trade publicly when it acquired Algos Pharmaceutical in 2000.
Endo expanded into Canada in 2014, creating Endo Internacional plc. At the same time, the company established new global headquarters in Dublin.
Endo Pharmaceuticals trades publicly on the NASDAQ under the ticker symbol ENDP, is a member of the S&P 500, is #766 in the Fortune 1000, has 3,371 employees, and had $2.66 billion in revenue in 2014.
Endo PharmaceuticalsEndo Pharmaceuticals was created in 1997 by a management buyout at DuPont Merck. At that time, the CEO, Executive Vice President of Operations, and another colleague purchased Endo Laboratories’ 12 brand products including Percoset, Percodan, and Opana, as well as the company’s generic products.
The company began to trade publicly when it acquired Algos Pharmaceutical in 2000.
Endo expanded into Canada in 2014, creating Endo Internacional plc. At the same time, the company established new global headquarters in Dublin.
History
Endo Pharmaceuticals trades publicly on the NASDAQ under the ticker symbol ENDP, is a member of the S&P 500, is #766 in the Fortune 1000, has 3,371 employees, and had $2.66 billion in revenue in 2014.